You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Vital update for Valneva’s COVID-19 vaccine

Valneva has announced further data emerging from a study of its inactivated COVID-19 vaccine, VLA2001. Meanwhile, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion for the use of VLA2001 in adults of 18 to 50 years of age.